| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Endothelial EA.hy926 cells are stimulated to produce NO by CORM-401 (100 μM; 1 h)[1]. Endoplasmic reticulum and plasma membrane pool-operated calcium channels are better coupled when CORM-401 (30 μM) is added, inducing peak calcium signaling [1]. CORM-401 (50 μM; 1h) dramatically lowers ROS generation and cell death caused by TNF-α/CHX and H2O2 [2]. The oxygen consumption rate of endothelial EA.hy926 cells is sustainedly increased by CORM-401 (0.5, 1 mM) [3]. While decreasing ECAR, CORM-401 (10, 30, and 100 μM) causes an increase in OCR that is concentration-dependent [3].
|
|---|---|
| References |
|
| Exact Mass |
330.902
|
|---|---|
| CAS # |
1001015-18-4
|
| Related CAS # |
1001040-67-0 (cation);1001015-18-4;
|
| PubChem CID |
168430661
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0.016
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
151
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[H+].[O+]#C[Mn+]1([SH-]C(N(CC([O-])=O)C)=S1)(C#[O+])(C#[O+])C#[O+]
|
| InChi Key |
BYBYPEYFKXEVIY-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C4H7NO2S2.4CO.Mn/c1-5(4(8)9)2-3(6)7;4*1-2;/h2H2,1H3,(H,6,7)(H,8,9);;;;;/p-1
|
| Chemical Name |
carbon monoxide;N-(carboxymethyl)-N-methylcarbamodithioate;manganese
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~75.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.55 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.55 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
